Just as we detected associations between the AD PRS and measures of AD pathology, polygenic risk for AD has been shown elsewhere to correlate with neuropathological phenotypes such as higher amyloid burden as measured with positron emission tomography (PET) (53, 54), volume loss in brain regions such as the hippocampus and entorhinal cortex as seen on MRI (55, 56), and levels of phosphorylated tau or amyloid beta in plasma or cerebrospinal fluid (57–59). Here, MAPT is linked to Alzheimer disease.